MARKET

FENC

FENC

Fennec Pharmaceuticals Inc
NASDAQ
7.62
-0.34
-4.27%
After Hours: 7.62 0 0.00% 16:00 12/16 EST
OPEN
7.99
PREV CLOSE
7.96
HIGH
7.99
LOW
7.55
VOLUME
152.68K
TURNOVER
--
52 WEEK HIGH
9.92
52 WEEK LOW
4.680
MARKET CAP
260.25M
P/E (TTM)
-30.2021
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at FENC last week (1208-1212)?
Weekly Report · 1d ago
Analysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (FENC) and Pfizer (PFE)
TipRanks · 12/09 15:50
Fennec Pharmaceuticals Supports New Trial for Hearing Loss Prevention in Cancer Treatment
TipRanks · 12/09 12:53
Fennec announces planned initiation of IST by City of Hope to evaluate PEDMARK
TipRanks · 12/09 12:20
FENNEC PHARMACEUTICALS ANNOUNCES INVESTIGATOR-SPONSORED TRIAL TO BE CONDUCTED BY CITY OF HOPE IN METASTATIC TESTICULAR GERM CELL TUMORS
Reuters · 12/09 12:00
FENNEC PHARMACEUTICALS INC - STUDY TO EVALUATE PEDMARK FOR PREVENTING CISPLATIN-INDUCED OTOTOXICITY
Reuters · 12/09 12:00
Stocks in play: Fennec Pharmaceuticals Inc.
Barchart · 12/09 08:34
Weekly Report: what happened at FENC last week (1201-1205)?
Weekly Report · 12/08 09:17
More
About FENC
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate, PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

Webull offers Fennec Pharmaceuticals Inc stock information, including NASDAQ: FENC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FENC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FENC stock methods without spending real money on the virtual paper trading platform.